BRIAN BRADY: Open Payments
NPI 1225613094 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,612 in 93 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $1,607 · 2025 $1,612
Food & beverage: $1,612
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $347 |
| E.R. Squibb & Sons, L.L.C. | 14 | $263 |
| Teva Pharmaceuticals USA, Inc. | 10 | $234 |
| ABBVIE INC. | 25 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $171 |
| Alkermes, Inc. | 8 | $160 |
| Janssen Pharmaceuticals, Inc | 4 | $119 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: INGREZZA, COBENFY, VRAYLAR, UZEDY, CAPLYTA, ARISTADA, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across MD — which companies pay providers there.
